AUCTORES
Globalize your Research

Clinical Orthopaedics and Trauma Care

Tamer A. Addissouky *

Open Access

Review Article

Regenerating Damaged Joints: The Promise of Tissue Engineering and Nanomedicine in Lupus Arthritis

Tamer A. Addissouky [1,2,3]*, Ibrahim El Tantawy El Sayed [2], Majeed M. A. Ali [1]

[1] Al-Hadi University College, Baghdad, Iraq.

[2] Department of Biochemistry, Science Faculty, Menoufia University, Menoufia, Egypt.

[3] MLS ministry of health, Alexandria, Egypt. - MLS ASCP, USA.

Corresponding Author: Tamer A. Addissouky, Al-HADI University College, Baghdad. Iraq. - Department of Biochemistry, Science Faculty, Menoufia University, Egypt. - MLS ministry of health, Alexandria, Egypt. - MLS, ASCP, USA; tedesoky@gmail.com; tedesoky@science.menofia.edu.eg, +79112205890.

Received date: January 24, 2024; **Accepted date:** February 09, 2024; **Published date:** February 29, 2024

Citation: Tamer A. Addissouky, Ibrahim El Tantawy El Sayed, and Majeed M. A. Ali. (2024), Regenerating Damaged Joints: The Promise of Tissue Engineering and Nanomedicine in Lupus Arthritis, *J Clinical Orthopaedics and Trauma Care*, 6(2); DOI: **10.31579/2694-0248/083**

Abstract

Background: Lupus osteoarthritis is a disabling complication of systemic lupus erythematosus (SLE) caused by persistent inflammation and biomechanical factors. The complex pathogenesis and heterogeneous clinical course pose management challenges.

Purpose: To review the etiology, clinical features, treatment, and prognosis of lupus osteoarthritis.

Main body: Lupus osteoarthritis stems from immune complex deposition, autoantibodies, and cytokines that damage joint tissues. Mechanical insultscoupled with altered joint biomechanics accelerate degeneration. The hands, wrists, and knees are most frequently involved, causing pain, stiffness, and reduced mobility. Radiographic hallmarks include joint space narrowing, periarticular osteopenia, and erosions. Composite tools like SLEDAI are used to quantify disease activity. Cardiovascular disease, osteoporosis, and infections are common comorbidities. Despite improved therapies, many patients develop disabling erosive arthritis within years of lupus diagnosis. Treatment entails lifestyle modification, analgesics, antimalarials, corticosteroids, immunosuppressants, injections, and surgery as needed. Emerging biologics, regenerative strategies, and precision medicine approaches tailored to molecular profiling offer promising directions to improve long-term outcomes. However, more research is required to halt joint damage and restore mobility in this challenging complication of SLE.

Conclusion: Lupus osteoarthritis remains a major contributor to morbidity in SLE warranting further research into pathogenetic mechanisms, predictive biomarkers, and personalized therapies to prevent irreversible joint damage.

Keywords: lupus osteoarthritis; systemic lupus erythematosus; inflammation; joint damage; precision medicine; biomarkers

I. Background

Lupus osteoarthritis is a type of secondary osteoarthritis caused by systemic lupus erythematosus (SLE). SLE is an autoimmune disease that can damage multiple organ systems, including the joints. The prevalence of lupus osteoarthritis varies globally, with rates ranging from 0.2% in Caucasian populations to 6.1% in Chinese populations. Women are 9 times more likely to develop lupus osteoarthritis compared to men. Onset is typically between ages 20-40 [1, 2]. Several risk factors for developing lupus osteoarthritis have been identified as depicted in **table 1**. Having a longstanding history of SLE significantly increases risk, as ongoing inflammation can damage joint tissues. The use of corticosteroids to treat SLE also elevates risk. Joint trauma, obesity, and older age are additional risk factors. Genetic factors may also play a role, as lupus osteoarthritis disproportionately affects non-Caucasian racial groups [3-5]. Lupus osteoarthritis imposes a substantial burden on patients and healthcare systems. Pain, stiffness, deformity, and

disability are common consequences and negatively impact quality of life. Depressive symptoms are also more prevalent in those with lupus arthritis compared to healthy controls or even those with non-lupus arthritis. Estimates suggest 20-30% of lupus patients will develop erosive arthritis. Treatment costs for lupus osteoarthritis remain high due to medications and surgeries required to manage symptoms [6].

Table 1: Risk factors for developing lupus osteoarthritis.

Risk Factor	Description
Long disease duration	Ongoing inflammation from SLE damages joints over time
Corticosteroid use	Impairs cartilage repair and alters joint biomechanics
Joint trauma	Can trigger localized inflammation and cartilage breakdown
Obesity	Excess mechanical loading on joints
Older age	Accumulation of joint damage with aging
Genetics	Higher risk in non-Caucasian populations suggests genetic factors

II. Pathogenesis

The underlying mechanisms driving the development of lupus osteoarthritis are complex and involve both inflammatory and biomechanical factors. Persistent inflammation stemming from systemic lupus erythematosus (SLE) is central to the pathogenesis. SLE leads to increased production of autoantibodies and cytokines that damage joint tissues, activating degradative enzymes and hindering cartilage repair [7-9].

Autoantibodies implicated in lupus osteoarthritis pathogenesis include anti-dsDNA, anti-collagen, anti-C1q, and rheumatoid factor. These can form immune complexes that deposit in the synovium and cartilage, triggering inflammatory cascades. Cytokines shown to have destructive effects in lupus arthritis include TNF-alpha, IL-1beta, IL-6, and IL-17. The resulting inflammation disrupts cartilage homeostasis and accelerate breakdown [10].

Abnormal joint mechanics also contribute by increasing stresses on damaged joint surfaces. Tendon ruptures and ligamentous laxity from corticosteroid use alter joint biomechanics. Muscle weakness and joint deformities like subluxation further disturb normal mechanics. These mechanical insults coupled with inflammation drive rapid joint deterioration [11]. Advances in systems biology and omics methodologies are providing new insights into disease mechanisms. Genomics, epigenomics, and proteomics are identifying molecular signatures and networks specific to lupus osteoarthritis. Integrative analyses will help delineate complex interactions between inflammatory mediators, biomechanical factors, and joint tissues that lead to irreversible damage. This knowledge promises to uncover new therapeutic targets and personalized strategies.

III. Clinical manifestations

The clinical presentation of lupus osteoarthritis is driven by progressive joint damage and inflammation. Patients typically experience pain, swelling, tenderness, and stiffness in affected joints. The hands, wrists, and knees are most commonly involved, but any diarthrodial joint can be impacted. Joint symptoms are often asymmetric. Morning stiffness lasting over 30 minutes and severe fatigue are also frequently reported. Various extra-articular manifestations may accompany the arthritis. Anemia, leukopenia, and thrombocytopenia are common hematologic abnormalities. Serositis, pulmonary disease, and neuropsychiatric symptoms can also occur as part of the underlying systemic lupus erythematosus [12-14]. Radiographic findings include periarticular osteopenia, marginal erosions, and progressive joint space narrowing as depicted in **table 2**. Advanced imaging like MRI reveals synovitis, tenosynovitis, and bone marrow lesions. Ultrasound can detect earlier erosive changes. Repeated imaging allows quantification of structural damage progression over time. Composite tools like the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) are used to assess current disease activity. Specific joint counts and serum biomarkers like ESR, CRP, and complement levels inform scoring [15, 16].

Table 2: Molecular Mediators of Synovial Inflammation in Knee OA.

Radiographic Finding	Description
Periarticular osteopenia	Reduced bone density around inflamed joints
Joint space narrowing	Loss of cartilage leads to narrowing of joint space
Marginal erosions	Breakdown of cartilage and bone at joint margins
Joint subluxation	Misalignment of joint surfaces due to ligament laxity

IV. Comorbidities and complications

Lupus osteoarthritis does not occur in isolation, but rather in the context of systemic lupus erythematosus (SLE) and associated comorbid conditions. Patients with lupus arthritis face elevated risks of cardiovascular disease, osteoporosis, and infections stemming from both the underlying lupus and its treatments. Multi-omics profiling techniques are being applied to disentangle the complex molecular interconnections between lupus, arthritis, and co-occurring conditions. Cardiovascular disease is a leading driver of early mortality in lupus. Accelerated atherosclerosis stems from overlapping risk factors and immune-mediated arterial damage. Chronic inflammation promotes endothelial dysfunction, while corticosteroid therapy compounds hyperlipidemia, diabetes, hypertension, and obesity. Antimalarials like hydroxychloroquine help reduce cardiovascular risk but many patients still suffer myocardial infarction, stroke, or peripheral vascular disease. Ongoing arthritis activity itself acts as an independent risk factor for atherosclerotic progression. Management requires vigilance for cardiovascular risk factors through regular EKG, lipid panel, and blood pressure monitoring [17-19]. Osteoporosis and increased fragility fracture risk also accompany lupus osteoarthritis. Underlying lupus can directly impair bone health, while

corticosteroids induce further bone loss. Chronic arthritis limits mobility, decreasing bone strength over time. Damage to joint structures alters biomechanical forces, contributing to focal osteopenia adjacent to inflamed joints. Early detection of osteopenia using DEXA scanning guides treatment with calcium, vitamin D, and bisphosphonates if needed. Addressing risk factors including vitamin D deficiency, smoking, alcohol use, and low BMI helps mitigate complications. Due to immunosuppression, infections represent another major concern in lupus arthritis. Herpes zoster, urinary tract infections, respiratory infections, salmonella, and listeria disproportionately affect those with lupus receiving corticosteroids and other immunosuppressants. Septic arthritis can arise, especially with intraarticular injections. Screening and vaccination against influenza, pneumococcus, HPV, hepatitis B, and COVID-19 are recommended. Prompt antibiotic treatment of suspected infections is key. Biologic agents require special caution due to higher serious infection risks [20-22]. Multi-omics approaches can provide molecular insights into comorbidity development in lupus osteoarthritis. Genomic analyses uncover genetic variants linked to cardiovascular, skeletal, and infectious complications. Epigenomics reveals chromatin modifications driving aberrant gene expression. Transcriptomics identify cytokine, growth factor and microRNA profiles underlying comorbid conditions. Proteomics detects biomarkers like autoantibodies that mediate organ damage. Metabolomics quantifies metabolic shifts contributing to accelerated atherosclerosis and bone loss. Integrating multi-omics data through systems biology networks will further unravel the complex biology connecting lupus, arthritis, and co-occurring illnesses [23-28].

V. Management of lupus osteoarthritis

Management of lupus osteoarthritis centers on relieving symptoms, maintaining function, and slowing joint damage identified as depicted in **table 3**. A multimodal approach is typically needed as no single treatment confers complete disease control. Initial management emphasizes lifestyle modifications and conservative therapies. Pharmacologic treatments, injections, surgery, and complementary medicine approaches may be utilized for patients with ongoing disease activity and progression. Emerging nanotechnology, regenerative medicine, precision medicine and pharmacogenomics strategies aim to repair joint structures and provide customized treatment based on biomarker profiles [29]. Lifestyle measures represent important foundations of lupus osteoarthritis management. Low-impact aerobic exercise helps maintain joint mobility and muscle strength without overloading damaged joints. Physical therapy under an occupational therapist or physiatrist can optimize exercise regimens. Weight loss reduces mechanical stress on weight-bearing joints. Assistive devices like splints, braces, and canes protect joints from further damage. Applying alternating heat and cold therapies and distraction techniques can alleviate pain during flares. Avoiding excess joint-straining activities, pacing activity throughout the day, and scheduling planned rest periods are also recommended [30-33]. If conservative lifestyle approaches prove inadequate for controlling symptoms, pharmacologic treatments are initiated. Non-steroidal anti-inflammatory drugs (NSAIDs) like ibuprofen and naproxen help relieve pain and inflammation by inhibiting cyclooxygenase enzymes. NSAIDs carry gastrointestinal and cardiovascular side effect risks with long-term use. Selective COX-2 inhibitor NSAIDs like celecoxib offer slightly improved safety profiles. Analgesics like acetaminophen and narcotics can be used adjunctively for pain relief. Low-dose oral corticosteroids such as prednisone suppress inflammation but side effects include osteoporosis, diabetes, and susceptibility to infections. Antimalarials like hydroxychloroquine have immunomodulatory and anti-inflammatory effects. Hydroxychloroquine has demonstrated efficacy for controlling lupus arthritis symptoms and is considered an anchor treatment. Immunosuppressants like methotrexate, azathioprine, mycophenolate mofetil and cyclosporine may be prescribed for patients with resistant disease. Biologic response-modifiers that target specific inflammatory mediators are emerging options but require further study for lupus osteoarthritis [34-46]. Intraarticular corticosteroid injections provide localized anti-inflammatory effects but should be used judiciously to limit joint damage. Repeated injections spaced 3-4 months apart are sometimes utilized for persistent synovitis in larger joints like the knees, ankles and elbows. Hyaluronic acid injections may supplement pharmacological treatment by restoring the lubricating properties of synovial fluid, but evidence for efficacy in lupus arthritis is limited. Nutraceuticals like chondroitin, glucosamine and avocado-soybean unsaponifiables have demonstrated benefits for osteoarthritic pain and may have adjunctive effects [47-49]. When joint damage is severe and unresponsive to other measures, surgical interventions may be warranted. Synovectomy removes inflamed synovial tissue. Tendon repairs can address tendon rupture secondary to corticosteroid use. Osteotomies realign joints to shift loading forces away from damaged cartilage. Total joint replacements provide pain relief and restore function in end-stage arthritis but outcomes are best when inflammation is well-controlled pre-operatively. Due to high failure rates, joint replacement surgery is often delayed as long as possible in lupus patients [50-52]. Some patients utilize complementary and alternative medicine approaches for lupus osteoarthritis management. Acupuncture may alleviate pain but supporting evidence is limited. Herbal remedies like thunder god vine andTripterygium wilfordii have anti-inflammatory and immunosuppressive properties in early research. Components of Traditional Chinese Medicine formulations like Duhuo Jisheng Wan have shown chondroprotective effects in vitro but require further study. More research is needed to establish the safety and efficacy of these complementary modalities. Caution is warranted with herbal remedies due to potential toxicity and drug interactions [53-57].

New frontiers in nanomedicine and regenerative medicine aim to repair and regenerate damaged joint tissues. Hydrogels, nanoparticles, and scaffolds fabricated from natural and synthetic biomaterials show promise for localized drug delivery and tissue engineering but are still early in development. Stem cell therapies like mesenchymal stem cell injections may have immunomodulatory and cartilage regenerating effects. Platelet-rich plasma provides growth factors that could stimulate healing. These novel biological treatments offer exciting potential but currently lack sufficient supporting evidence. Their long-term impacts and ideal methods of application remain uncertain. Carefully conducted clinical trials are needed to evaluate efficacy and safety [58, 59]. Looking ahead, pharmacogenomics and precision medicine approaches tailored to individual genetic profiles and biomarkers could transform treatment. Gene expression patterns, autoantibody specificities, cytokine levels, and synovial pathobiology vary across lupus osteoarthritis patients and may predict response to therapies. Matching treatments to pathogenic mechanisms identified through molecular profiling promises improved outcomes while minimizing treatment burdens. As science uncovers more connections between genetic makeup and disease phenotype, treatments can become more targeted and personalized. While still largely aspirational, precision medicine strategies offer hope for the future.

Table 3: Emerging treatments for lupus osteoarthritis.

Treatment	Description
Biologics	Target specific cytokines and immune pathways driving inflammation
Nanoparticle drug delivery	Localize therapies directly to joint tissue
Tissue engineering	Use scaffolds, cells, and growth factors to regenerate cartilage
Stem cell therapy	Mesenchymal stem cells have regenerative and anti-inflammatory effects
Platelet rich plasma	Provides growth factors that may stimulate joint healing
Pharmacogenomics	Match treatments to patient's genetic profile

VI. Future directions

There is a critical need to identify distinct molecular subtypes through unbiased omics profiling and machine learning approaches. Gene expression profiling, proteomics, metabolomics, and synovial histopathology may reveal distinct subsets with unique biomarker signatures. These molecular subtypes could be linked to clinical trajectory and treatment response, facilitating precision medicine. Developing predictive multi-biomarker panels for prognosis, damage accrual, and comorbidities through integration of multi-omics and deep learning represents a key future priority. Novel therapeutics targeted to specific pathogenic pathways hold promise to transform lupus osteoarthritis treatment. Small molecule inhibitors, biologics, and nanotherapies targeting cytokines, B and T cells, osteoclasts, and angiogenesis pathways should be evaluated. Optimal treatment may require combination strategies based on an individual's molecular profile. To enable precision medicine, biomarkers and algorithms to predict therapeutic response must be refined through multi-omics screens and artificial intelligence. Additionally, new chemical entities discovered through computational drug design can be optimized using high throughput screening and structure-activity analyses [59-62]. Regenerative medicine and tissue engineering have potential to reverse existing joint damage in lupus osteoarthritis. Mesenchymal stem cells, growth factors, bio scaffolds and hydrogels could stimulate cartilage and bone regeneration. Optimizing scaffold biomechanics, cell sourcing, and bioactive compound delivery will be critical. Combining regenerative approaches with advanced gene editing tools like CRISPR could enable durable joint tissue restoration. Rigorous clinical trials are required to demonstrate safety, efficacy and long-term impacts of these emerging biologics. Monitoring repair tissue integration and mechanics using advanced imaging will provide valuable insights [63-66]. Human and animal model studies should further delineate interactions between biomechanical stress and inflammatory pathways in lupus osteoarthritis progression. Elucidating mechanisms by which altered joint kinematics and muscle forces impact synovial inflammation, cartilage breakdown, and periarticular bone loss remains an important goal. This knowledge promises to reveal new targets for interrupting degenerative pathways amplified by biomechanical forces. Developing personalized biomechanical models of joint loading through integration of musculoskeletal imaging, gait analysis, and finite element modeling represents a fruitful research direction [67-68]. Leveraging big data science, sensors, and digital health tools could enable improved disease monitoring, treatment adherence, patient education and self-management in lupus osteoarthritis. Wearable devices and smartphone apps that capture real-world disease activity data can be integrated with electronic health records and clinical decision support systems to optimize treatment. Machine learning applied to multimodal data sources may uncover new predictive and prognostic indicators. Telemedicine and mobile health technologies have potential to improve access and quality of multidisciplinary care. Further research should evaluate the impact of digital health technologies on patient-reported outcomes [69-72].

VII. Conclusion

Lupus osteoarthritis is a severe complication of systemic lupus erythematosus associated with pain, disability, and reduced quality of life. The complex interplay between ongoing inflammation, altered joint mechanics, and tissue damage drives disease progression. While treatment has improved, many patients still develop erosive arthritis and accrue joint damage over time. A systems medicine approach leveraging multi-omics technologies and computational models holds promise to unravel disease heterogeneity, predictive biomarkers, and molecular targets for personalized therapy. Advances in tissue engineering, nanotechnology, and digital health innovation may transform future management. However, lupus osteoarthritis remains a challenging condition warranting further research to improve long-term outcomes and restore joint health.

VIII. Recommendations

Further studies should evaluate efficacy and safety of novel biologics and small molecule inhibitors targeting pathogenic pathways identified through omics profiling of synovial tissue and circulating cells. Combination treatment strategies matched to molecular disease signatures require exploration. Regenerative medicine therapies aimed at durable joint tissue restoration should be rigorously tested in progressively larger randomized controlled trials. Development of predictive algorithms integrating multi-omics data and machine learning may enable precision medicine approaches. Digital health technologies that enhance disease monitoring and patient self-management deserve evaluation in lupus osteoarthritis populations. Multidisciplinary care and patient support systems are crucial to optimize outcomes.

List of abbreviations

SLE - systemic lupus erythematosus

ESR - erythrocyte sedimentation rate

CRP - C-reactive protein

SLEDAI - Systemic Lupus Erythematosus Disease Activity Index

SLICC - Systemic Lupus International Collaborating Clinics

DMARD - disease-modifying antirheumatic drug

NSAID - nonsteroidal anti-inflammatory drug

TNF - tumor necrosis factor

IL - interleukin

MRI - magnetic resonance imaging

DEXA - dual-energy x-ray absorptiometry

BMI - body mass index

HPV - human papillomavirus

COX - cyclooxygenase

Declarations:

Ethics approval and consent to participate: Not Applicable

Consent for publication: Not Applicable

Availability of data and materials: all data are available and sharing is available as well as publication.

Competing interests: The authors hereby that they have no competing interests.

Funding: Corresponding author supplied all study materials. There was no further funding for this study.

Authors' contributions: The authors completed the study protocol and were the primary organizers of data collection and the manuscript's draft and revision process. Tamer A. Addissouky wrote the article and ensured its accuracy. All authors contributed to the discussion, assisted in designing the study and protocol and engaged in critical discussions of the draft manuscript.

Acknowledgements: The authors thank all the researchers, editors, reviewers, and the supported universities that have done great efforts on their studies. Moreover, we are grateful to the editors, reviewers, and reader of this journal.

References

1. Shumilova, Anastasiia, and Edward M. Vital. Musculoskeletal Manifestations of Systemic Lupus Erythematosus. Best Practice & Research Clinical Rheumatology, (2023): 101859. Accessed January 19, 2024.
2. Petri, M.; Aringer, M.; Ayoub, I.; Salem Almaani; Brunner, H. I.; Dall'Era, M.; Jiang, M.; Furie, R.; Greco, J.; Goldblatt, F.; Huggins, J.; Huizinga, T.; Isenberg, D.; Li, N. L.; Monahan, R. C.; Parikh, S.; Pisetsky, D. S.; Puravath, A. P.; Rovin, B. H.; Wallace, D. J. (2023). Systemic Lupus Erythematosus. Springer eBooks 2023, 167–212.
3. Xiao, XY., Chen, Q., Shi, YZ. et al. (2023). Risk factors of systemic lupus erythematosus: an overview of systematic reviews and Mendelian randomization studies. Adv Rheumatol 63, 42.
4. Addissouky, T.A., El Sayed, I.E.T., Ali, M.M.A. et al. (2024). Oxidative stress and inflammation: elucidating mechanisms of smoking-attributable pathology for therapeutic targeting. Bull Natl Res Cent 48, 16.
5. Refai RH, Hussein MF, Abdou MH, Abou-Raya AN. (2023). Environmental risk factors of systemic lupus erythematosus: a case-control study. Sci Rep. 2023 Jun 23;13(1):10219.
6. Pisetsky DS, Eudy AM, Clowse MEB, Rogers JL. (2021). The Categorization of Pain in Systemic Lupus Erythematosus. Rheum Dis Clin North Am. 2021 May;47(2):215-228.
7. Li, R., Yang, C., Tang, YY. et al. (2023). Association between endothelin-1 and systemic lupus erythematosus: insights from a case–control study. Sci Rep 13, 15970.
8. El-Akhras BA, Talaat RM, El-Masry SA, Bassyouni IH, El-Sayed IH, Ali YB. (2023). Crosstalk between miR-146a and pro-inflammatory cytokines in patients with systemic lupus erythematosus. Int J Immunopathol Pharmacol. 2023 Jan-Dec; 37:3946320231154998.
9. Xiang, Yu, Mingxue Zhang, Die Jiang, Qian Su, and Jianyou Shi. (2023). The Role of Inflammation in Autoimmune Disease: A Therapeutic Target. Frontiers in Immunology 14, (2023): 1267091. Accessed January 19, 2024.
10. Fenton KA, Pedersen HL. (2023). Advanced methods and novel biomarkers in autoimmune diseases a review of the recent years progress in systemic lupus erythematosus. Front Med (Lausanne). 2023 Jun 23; 10:1183535.
11. Wen, ZQ., Lin, J., Xie, WQ. et al. (2023). Insights into the underlying pathogenesis and therapeutic potential of endoplasmic reticulum stress in degenerative musculoskeletal diseases. Military Med Res 10, 54.
12. Mihai, Ancuta, Constantin Caruntu, Ciprian Jurcut, Florin Cristian Blajut, Mihnea Casian, Daniela Opris-Belinski, Ruxandra Ionescu, and Ana Caruntu. (2023). The Spectrum of Extraglandular Manifestations in Primary Sjögren's Syndrome Journal of Personalized Medicine 13, no. 6: 961.
13. AlOmair M, AlMalki H, AlShahrani M, Mushait H, Al Qout M, Alshehri T, AlAlyani R, Algarni A, Almaker Y, Madkli E. (2023). Clinical Manifestations of Systemic Lupus Erythematosus in a Tertiary Center in Saudi Arabia. Cureus. 2023 Jun 30;15(6):e41215.
14. Shumilova, Anastasiia, and Edward M. (2023). Vital. Musculoskeletal Manifestations of Systemic Lupus Erythematosus. Best Practice & Research Clinical Rheumatology, (2023): 101859. Accessed January 19, 2024.
15. El genedi, S.H., Salem, M.N., Farid, M. et al. (2023). Detection of joint involvement in patients with systemic lupus erythematosus using musculoskeletal ultrasound and its correlation with disease activity. Beni-Suef Univ J Basic Appl Sci 12, 34.
16. Song Y, Kirsch G, Jarjour W. (2023). The Utility of Ultrasound in Evaluating Joint Pain in Systemic Lupus Erythematosus: Looking beyond Fibromyalgia. J Pers Med. 2023 Apr 28;13(5):763.
17. Koo M, Hsu CW, Lu MC. (2023). Increased Risk of Developing Systemic Lupus Erythematosus and Rheumatoid Arthritis in Patients with Primary Sjögren's Syndrome-A Secondary Cohort Analysis of Nationwide, Population-Based Claims Data. J Clin Med. 2023 Jun 20;12(12):4157.
18. Gasparyan, A.Y. (2023). Cardiovascular manifestations and comorbidities in rheumatic diseases: perspectives on timely diagnosis, prevention, and treatment. Clin Rheumatol 42, 2531–2533.
19. T A Addissouky, A A Khalil, A E El Agroudy, (2023). Assessment of potential biomarkers for early detection and management of Glomerulonephritis patients with diabetic diseases, American Journal of Clinical Pathology, Volume 160, Issue Supplement_1, November 2023, Pages S18–S19.
20. Addissouky TA, Ali M, El Tantawy El Sayed I, Wang Y. (2023). Revolutionary Innovations in Diabetes Research: From Biomarkers to Genomic Medicine. IJDO 2023; 15 (4) :228-242.

21. Addissouky TA, El Tantawy El Sayed I, Ali MMA, Wang Y, El Baz A, Elarabany N, et al. (2024). Shaping the Future of Cardiac Wellness: Exploring Revolutionary Approaches in Disease Management and Prevention. J Clin Cardiol. 2024;5(1):6-29.
22. Liu, Y.; Deng, S.; Song, Z.; Zhang, Q.; Guo, Y.; Yu, Y.; Wang, Y.; Li, T.; Fayed; Addissouky, T. A.; Mao, J.; Zhang, Y. (2021). MLIF Modulates Microglia Polarization in Ischemic Stroke by Targeting EEF1A1. Frontiers in Pharmacology 2021, 12.
23. T A Addissouky, A E El Agroudy, A A Khalil, (2023). Developing a Novel Non-invasive Serum-based Diagnostic Test for Early Detection of Colorectal Cancer, American Journal of Clinical Pathology, Volume 160, Issue Supplement_1, November 2023, Page S17.
24. Addissouky TA, El Tantawy El Sayed I, Ali MMA, Wang Y, El Baz A, Khalil AA, et al. (2023). Can Vaccines Stop Cancer Before It Starts? Assessing the Promise of Prophylactic Immunization Against High-Risk Preneoplastic Lesions J Cell Immunol. 2023;5(4):127-126.
25. T A Addissouky, A A Khalil, (2020). Detecting Lung Cancer Stages Earlier By Appropriate Markers Rather Than Biopsy And Other Techniques, American Journal of Clinical Pathology, Volume 154, Issue Supplement_1, October 2020, Pages S146–S147.
26. Scheuing, William J., Anthony M. Reginato, Mery Deeb, and Sevtap Acer Kasman. (2023). The Burden of Osteoarthritis: Is It a Rising Problem? Best Practice & Research Clinical Rheumatology 37, no. 2 (2023): 101836. Accessed January 19, 2024.
27. Martina Frodlund, Andreas Jönsen, Lauren Remkus, Gunilla Telg, Fabian Söderdahl, Dag Leonard, (2023). Glucocorticoid treatment in SLE is associated with infections, comorbidities and mortality—a national cohort study, Rheumatology, 2023; kead348.
28. Corker, Alexa, Maya Learmonth, David M. Patrick, Kristine Y., and Justin P. Van Beusecum. (2023). Cardiac and Vascular Complications in Lupus: Is There a Role for Sex? Frontiers in Immunology 14, (2023): 1098383. Accessed January 19, 2024.
29. Md Yusof, Md Y., Eve M. Smith, Sammy Ainsworth, Kate Armon, Michael W. Beresford, Morgan Brown, Lindsey Cherry et al. (2023). Management and Treatment of Children, Young People and Adults with Systemic Lupus Erythematosus: British Society for Rheumatology Guideline Scope. Rheumatology Advances in Practice 7, no. 3 (2023). Accessed January 19, 2024.
30. El Miedany Y, et al. (2023). Egyptian recommendations for the management of systemic lupus erythematosus: a consensus, evidence-based, clinical practice guidelines for treat-to-target management. Egypt Rheumatol Rehabil. 2023;50(1):23.
31. Yalavarthi B, Summerville J, Farahani N, et al. (2023). Recommendations for Improving Systemic Lupus Erythematosus Care From Black Adults: A Qualitative Study. JAMA Netw Open. 2023; 6(10):e2340688.
32. Muñoz-Grajales, Carolina, Esin B. Yilmaz, Elisabet Svenungsson, and Zahi Touma. (2023). Systemic Lupus Erythematosus and Damage: What Has Changed over the past 20 Years? Best Practice & Research Clinical Rheumatology, (2023): 101893. Accessed January 19, 2024.
33. Parodis I, Girard-Guyonvarc'h C, Arnaud L, et al (2023). EULAR recommendations for the non-pharmacological management of systemic lupus erythematosus and systemic sclerosis Annals of the Rheumatic Diseases Published Online First: 10 July 2023.
34. Addissouky, T.A., Sayed, I.E.T.E., Ali, M.M.A. et al. (2024). Latest advances in hepatocellular carcinoma management and prevention through advanced technologies. Egypt Liver Journal 14, 2 (2024).
35. Addissouky TA, Ali MMA, El Tantawy El Sayed I, Wang Y, El Baz A, Elarabany N, et al. (2023). Preclinical Promise and Clinical Challenges for Innovative Therapies Targeting Liver Fibrogenesis. Arch Gastroenterol Res. 2023;4(1):14-23.
36. Addissouky, T.A., Wang, Y., Megahed, F.A.K. et al. (2021). Novel biomarkers assist in detection of liver fibrosis in HCV patients. Egypt Liver Journal 11, 86.
37. Addissouky, T.A., Ayman E. El-Agroudy, Abdel Moneim A.K. El-Torgoman and 1Ibrahim E. El-Sayed, (2019). Efficacy of Biomarkers in Detecting Fibrosis Levels of Liver Diseases. IDOSI Publications, World Journal of Medical Sciences, Volume 16, Issue (1): PP. 11-18, March 2019, ISSN 1817-3055.
38. Addissouky, T.A., Ayman E. El Agroudy, Abdel Moneim A.K. El-Torgoman, Ibrahim El Tantawy El Sayed, Eman Mohamad Ibrahim, (2019). Efficiency of alternative markers to assess liver fibrosis levels in viral hepatitis B patients, Allied Academies Publications, Biomedical Research, Volume 30, Issue (2): PP. 351-356, April 2019; ISSN 0970 938X.
39. Addissouky, T.A., (2019). Detecting Liver Fibrosis by Recent Reliable Biomarkers in Viral Hepatitis Patients, American Journal of Clinical Pathology, Volume 152, Issue Supplement_1, October 2019, Page S85.
40. El Agroudy, A. E., Elghareb, M. S., Addissouky, T. A., Elshahat, E. H., & Hafez, E. H. (2016). Serum hyaluronic acid as a non-invasive biomarker to predict liver fibrosis in viral hepatitis patients. Journal of Biochemical and Analytical Research, 43(2), 108377.
41. El Agroudy, A. E., Elghareb, M. S., Addissouky, T. A., Elshahat, E. H., & Hafez, E. H. (2016). Biochemical study of some non-invasive markers in liver fibrosis patients. Journal of Biochemical and Analytical Research, 43(2), 108375.
42. Addissouky, T.A., et al. (2020). Efficiency of mixture of olive oil and figs as an antiviral agent: a review and perspective, International Journal of Medical Science and Health Research, ISSN:2581-3366, Volume 4, Issue 4, Aug 2020, page 107-111.
43. T A Addissouky, A A Khalil, A E El Agroudy, (2023). Assessing the Efficacy of a Modified Triple Drug Regimen Supplemented with Mastic Gum in the Eradication of Helicobacter pylori Infection, American Journal of Clinical Pathology, Volume 160, Issue Supplement_1, November 2023, Page S19.
44. Tenti, Sara, Olivier Bruyère, Sara Cheleschi, Yves Reginster, Nicola Veronese, and Antonella Fioravanti. (2023). An Update on the Use of Conventional and Biological Disease-modifying Anti-rheumatic Drugs in Hand Osteoarthritis. Therapeutic Advances in Musculoskeletal Disease, (2023). Accessed January 19, 2024.
45. Amirsaadat, Soumayeh, Halimeh Amirazad, Ramin Hashemihesar, and Nosratollah Zarghami. (2023). An Update on the Effect of Intra-articular Intervention Strategies Using Nanomaterials in Osteoarthritis: Possible Clinical Application. Frontiers in Bioengineering and Biotechnology 11, (2023): 1128856. Accessed January 19, 2024.
46. Lin, Shu, and Zhen Chen. (2023). Current Progress in Treating Systemic Lupus Erythematosus Using Exosomes/MicroRNAs. Cell Transplantation, (2023). Accessed January 19, 2024.

47. Song Y, Kirsch G, Jarjour W. (2023). The Utility of Ultrasound in Evaluating Joint Pain in Systemic Lupus Erythematosus: Looking beyond Fibromyalgia. J Pers Med. 2023 Apr 28;13(5):763.
48. Xu, Mingze and Ji, Yunhan. (2023). Immunoregulation of synovial macrophages for the treatment of osteoarthritis Open Life Sciences, vol. 18, no. 1, 2023, pp. 20220567.
49. Ren, W., Zhao, L., Sun, Y. et al. (2023). HMGB1 and Toll-like receptors: potential therapeutic targets in autoimmune diseases. Mol Med 29, 117.
50. Braun S, Flevas DA, Sokrab R, Ricotti RG, Rojas Marcos C, Pearle AD, Sculco PK. (2023). De Novo Synovial Chondromatosis following Primary Total Knee Arthroplasty: A Case Report. Life (Basel). 2023 Jun 10;13(6):1366.
51. Rehman A, Choudhari J, Shehryar A, Affaf M, Ata H, Batool W, Khan B, Mehra I, Gasim RW, Masood QF, Anika NN, Rehman S. (2023). Harmonizing Medicine and Surgery in the Pursuit of Boolean Remission: A Rheumatological Magnum Opus. Cureus. 2023 Nov 3;15(11):e48205.
52. Zeng, Weinan1; Yu, Zeping1; Wang, Simeng2; Chen, Anjing1; Zeng, Yiping3; Yang, Qingjun3; Li, Yujuan1; Li, Qi1; Zhou, Zongke1. (2023). Long-term results of synovectomy in total knee arthroplasty: a prospective, randomized controlled trial. Chinese Medical Journal 136(1):p 73-81, January 5, 2023.
53. Addissouky TA, Ali MMA, El Tantawy El Sayed I, Wang Y. (2023). Recent Advances in Diagnosing and Treating Helicobacter pylori through Botanical Extracts and Advanced Technologies. Arch Pharmacol Ther. 2023;5(1):53-66.
54. Addissouky, T.A., Wang, Y., El Sayed, I.E. et al. (2023). Recent trends in Helicobacter pylori management: harnessing the power of AI and other advanced approaches. Beni-Suef Univ J Basic Appl Sci 12, 80.
55. Marinho, António, José Delgado Alves, Jorge Fortuna, Raquel Faria, Isabel Almeida, Glória Alves, João Araújo Correia et al. (2023). Biological Therapy in Systemic Lupus Erythematosus, Antiphospholipid Syndrome, and SjöGren'S Syndrome: Evidence- and Practice-based Guidance. Frontiers in Immunology 14, (2023): 1117699. Accessed January 19, 2024.
56. Islam, Muhammad T., Chandan Sarkar, Rajib Hossain, Md. S. Bhuia, Ileana Mardare, Marzhan Kulbayeva, Alibek Ydyrys et al. (2023). Therapeutic Strategies for Rheumatic Diseases and Disorders: Targeting Redox Imbalance and Oxidative Stress. Biomedicine & Pharmacotherapy 164, (2023): 114900. Accessed January 19, 2024.
57. Parodis I, Gomez A, Tsoi A, Chow JW, Pezzella D, Girard C, Stamm TA, Boström C. (2023). Systematic literature review informing the EULAR recommendations for the non-pharmacological management of systemic lupus erythematosus and systemic sclerosis. RMD Open. 2023 Aug;9(3):e003297.
58. Lee, Bong-Woo, and Seung-Ki Kwok. (2023). Mesenchymal Stem/Stromal Cell-Based Therapies in Systemic Rheumatic Disease: From Challenges to New Approaches for Overcoming Restrictions International Journal of Molecular Sciences 24, no. 12: 10161.
59. P Singh R, S Bischoff D, S Singh S, H Hahn B. (2023). Peptide-based immunotherapy in lupus: Where are we now? Rheumatol Immunol Res. 2023 Sep 27;4(3):139-149.
60. Guo, J., Zhang, H., Lin, W. et al. (2023). Signaling pathways and targeted therapies for psoriasis. Sig Transduct Target Ther 8, 437.
61. Li, X., Peng, X., Zoulikha, M. et al. (2024). Multifunctional nanoparticle-mediated combining therapy for human diseases. Sig Transduct Target Ther 9, 1.
62. Mehrani, Yeganeh, Rasool Rahimi Junqani, Solmaz Morovati, Hossein Mehrani, Negar Karimi, and Samaneh Ghasemi. (2023). The Importance of Neutrophils in Osteoarthritis: Current Concepts and Therapeutic Perspectives Immuno 3, no. 3: 250-272.
63. Murphy EJ, Fehrenbach GW, Abidin IZ, Buckley C, Montgomery T, Pogue R, Murray P, Major I, Rezoagli E. (2023). Polysaccharides-Naturally Occurring Immune Modulators. Polymers (Basel). 2023 May 19;15(10):2373.
64. Zhang, Yuelong, Huangming Zhuang, Xunshan Ren, Fuze Jiang, and Panghu Zhou. (2023). Therapeutic Effects of Different Intervention Forms of Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Osteoarthritis. Frontiers in Cell and Developmental Biology 11, (2023): 1246504. Accessed January 19, 2024.
65. Chen, Ye, Rui-Juan Cheng, Yinlan Wu, Deying Huang, Yanhong Li, and Yi Liu. (2024). Advances in Stem Cell-Based Therapies in the Treatment of Osteoarthritis International Journal of Molecular Sciences 25, no. 1: 394.
66. Zhu X, Ma D, Yang B, An Q, Zhao J, Gao X, Zhang L. (2023). Research progress of engineered mesenchymal stem cells and their derived exosomes and their application in autoimmune/inflammatory diseases. Stem Cell Res Ther. 2023 Apr 11;14(1):71.
67. Zeng, J., Jiang, X., Jiang, M. et al. (2023). Bioinformatics analysis of hub genes as osteoarthritis prognostic biomarkers. Sci Rep 13, 22894.
68. Toumi E, Mezouar S, Plauzolles A, Chiche L, Bardin N, Halfon P, Mege JL. (2023). Gut microbiota in SLE: from animal models to clinical evidence and pharmacological perspectives. Lupus Sci Med. 2023 Feb;10(1):e000776.
69. Danieli, Maria G., Silvia Brunetto, Luca Gammeri, Davide Palmeri, Ilaria Claudi, Yehuda Shoenfeld, and Sebastiano Gangemi. (2024). Machine Learning Application in Autoimmune Diseases: State of Art and Future Prospectives. Autoimmunity Reviews 23, no. 2 (2024): 103496. Accessed January 19, 2024.
70. Vaskimo, Lotta M., Georgy Gomon, Najib Naamane, Heather J. Cordell, Arthur Pratt, and Rachel Knevel. (2023). The Application of Genetic Risk Scores in Rheumatic Diseases: A Perspective Genes 14, no. 12: 2167.
71. Hackshaw KV, Yao S, Bao H, de Lamo Castellvi S, Aziz R, Nuguri SM, Yu L, Osuna-Diaz MM, Brode WM, Sebastian KR, Giusti MM, Rodriguez-Saona L. (2023). Metabolic Fingerprinting for the Diagnosis of Clinically Similar Long COVID and Fibromyalgia Using a Portable FT-MIR Spectroscopic Combined with Chemometrics. Biomedicines. 2023 Oct 5;11(10):2704.
72. Stafie CS, Sufaru IG, Ghiciuc CM, Stafie II, Sufaru EC, Solomon SM, Hancianu M. (2023). Exploring the Intersection of Artificial Intelligence and Clinical Healthcare: A Multidisciplinary Review. Diagnostics (Basel). 2023 Jun 7;13(12):1995.

DOI:10.31579/2694-0248/083